Sector News

AstraZeneca divests asthma and rhinitis drug rights to Covis Pharma

December 7, 2018
Life sciences

AstraZeneca has completed its $350m sale of its rights to asthma drug Alvesco (ciclesonide) and nasal sprays Omnaris and Zetonna (ciclesonide) to Switzerland-based Covis Pharma.

The divested rights by the UK-based AstraZeneca to Covis Pharma cover markets outside the US and the US royalties for the three over-the-counter (OTC) drugs.

In 2017, AstraZeneca earned a combined $106m from the sales of Alvesco, Zetonna and Omnaris.

Alvesco is an inhaled anti-inflammatory maintenance therapy that is administered through a metered-dose inhaler to help control persistent asthma.

Both Omnaris and Zetonna were developed for the treatment of nasal symptoms resulting from seasonal allergic and allergic/non-allergic perennial rhinitis.

The active ingredient across all the three OTC drugs is ciclesonide, a synthetic corticosteroid that is known to play a role in reducing inflammation.

The deal, which was announced in November 2018, does not include the transfer of any employees or facilities of the pharma major to the Swiss company.

As per the terms of the deal, Covis Pharma will also make conditional sales-related payments for the three drugs of up to $21m to AstraZeneca over four years starting from 2019.

Last year, the Swiss pharma company acquired the US market rights of ciclesonide products Alvesco (ciclesonide) Inhalation Aerosol, Omnaris (ciclesonide) Nasal Spray, and Zetonna (ciclesonide) Nasal Aerosol from Sunovion Pharmaceuticals.

For AstraZeneca, the sale of the asthma and rhinitis drug rights to Covis Pharma is part of its strategic objectives to divest parts of its portfolio to allocate resources to develop new medicines to address unmet patient needs.

AstraZeneca, in a statement, said: “As AstraZeneca will not maintain a significant ongoing interest in the medicines, the upfront payment, net of a significant, non-cash derecognition of an intangible asset will be reported as Other Operating Income & Expense in the Company’s financial statements in the fourth quarter of 2018. The agreement does not affect the Company’s financial guidance for 2018.”

Last month, the company agreed to divest the US rights of its respiratory drug Synagis (palivizumab) to Swedish Orphan Biovitrum (Sobi) in a deal worth $1.5bn.

Source: PBR

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.